Key facts
- It has raised $95.0M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in May 2025.
- Notable investors include Samsung Venture Investment, Washington University in St. Louis, GHR Foundation, Alzheimers Drug Discovery Foundation, Diagnostics Accelerator — 9 tracked in total.
- C2N Diagnostics has filed 3 Form Ds with the SEC since 2024, most recently May 2025 ($10.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for C2N Diagnostics
Funding rounds
2 roundsAbout C2N Diagnostics
Provider of specialty diagnostic testing services intended to offer novel diagnostics for Alzheimer's disease. The company provides precise, accurate, and sensitive mass spectrometry-based analysis for identifying, quantifying, and monitoring proteins, fragments, and other biomolecules implicated in neurological disorders, enabling doctors to assess and characterize neurocognitive conditions.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2007
- Employees
- 98
- Website
- c2n.com/
- Ownership
- Privately Held (backing)
C2N Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in C2N Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on C2N Diagnostics in its N-PORT filings yet. We sweep new filings monthly.